All Outputs (4)

Exploring practice and perspectives on shared decision-making about osteoporosis medicines in Fracture Liaison Services: the iFraP development qualitative study (2024)
Journal Article
Bullock, L., Manning, F., Hawarden, A., Fleming, J., Leyland, S., Clark, E. M., …Paskins, Z. (in press). Exploring practice and perspectives on shared decision-making about osteoporosis medicines in Fracture Liaison Services: the iFraP development qualitative study. Archives of Osteoporosis, 19(1), Article 50. https://doi.org/10.1007/s11657-024-01410-6

Summary Interviews and focus groups with patients, FLS clinicians, and GPs identified challenges relating to clinical and shared decision-making about bone health and osteoporosis medicines. Findings will inform the development of the multicomponent... Read More about Exploring practice and perspectives on shared decision-making about osteoporosis medicines in Fracture Liaison Services: the iFraP development qualitative study.

A person-centred consultation intervention to improve shared decision-making about, and uptake of, osteoporosis medicines (iFraP): a pragmatic, parallel-group, individual randomised controlled trial protocol (2024)
Journal Article
Bullock, L., Nicholls, E., Cherrington, A., Butler-Walley, S., Clark, E. M., Fleming, J., …Paskins, Z. (in press). A person-centred consultation intervention to improve shared decision-making about, and uptake of, osteoporosis medicines (iFraP): a pragmatic, parallel-group, individual randomised controlled trial protocol. NIHR Open Research, 4(14), https://doi.org/10.3310/nihropenres.13571.1

Background Good quality shared decision-making (SDM) conversations involve people with, or at risk of osteoporosis and clinicians collaborating to decide, where appropriate, which evidence-based medicines best fit the person’s life, beliefs, and val... Read More about A person-centred consultation intervention to improve shared decision-making about, and uptake of, osteoporosis medicines (iFraP): a pragmatic, parallel-group, individual randomised controlled trial protocol.

Barriers and facilitators in diagnosing axial spondyloarthritis: a qualitative study (2024)
Journal Article
Hay, C. A., Packham, J., Prior, J. A., Mallen, C. D., & Ryan, S. (2024). Barriers and facilitators in diagnosing axial spondyloarthritis: a qualitative study. Rheumatology International, 44, 863–884. https://doi.org/10.1007/s00296-024-05554-z

Diagnosis of axial spondyloarthritis (axSpA) is frequently delayed for years after symptom onset. However, little is known about patient and healthcare professional (HCP) perspectives on barriers and facilitators in axSpA diagnosis. This study explor... Read More about Barriers and facilitators in diagnosing axial spondyloarthritis: a qualitative study.

EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update. (2024)
Journal Article
Moseng, T., Vliet Vlieland, T. P. M., Battista, S., Beckwée, D., Boyadzhieva, V., Conaghan, P. G., …Østerås, N. (in press). EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update. Annals of the Rheumatic Diseases, https://doi.org/10.1136/ard-2023-225041

Hip and knee osteoarthritis (OA) are increasingly common with a significant impact on individuals and society. Non-pharmacological treatments are considered essential to reduce pain and improve function and quality of life. EULAR recommendations for... Read More about EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update..